New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
08:04 EDTCLSNCelsion formalizing program to develop ThermoDox
Celsion announced that the company is formalizing a program to pursue the development of ThermoDox to investigate applications for treating brain cancer tumors, notably Glioblastoma Multiforme or GBM. In addition to jointly submitting multiple grant applications, the company is also pursuing preclinical studies in collaboration with Costas D. Arvanitis at the Brigham and Women's Hospital and Harvard Medical School.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
08:18 EDTCLSNCelsion's Thermodox for breast cancer shows positive Phase 2 results
Celsion announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses, 2 partial responses and 1 patient with stable disease. These data are consistent with the previously reported positive Phase 1 data in RCWBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use